1,068
Views
0
CrossRef citations to date
0
Altmetric
Licensed Vaccines – Research Article

A simulated, randomized study on the safety and immunogenicity of three consecutive commercial-scale batches of the CTN-1V strain human rabies vaccine to verify the inter-batch consistency

, , , , , , , , , , , , ORCID Icon & ORCID Icon show all
Article: 2138049 | Received 11 Jul 2022, Accepted 16 Oct 2022, Published online: 21 Nov 2022

References

  • Hm F Jr, Petersen BW, Robertson KL, Rupprecht CE. Rabies: still a uniformly fatal disease? Historical occurrence, epidemiological trends, and paradigm shifts. Curr Infect Dis Rep. 2012;14(4):1–9. doi:10.1007/s11908-012-0268-2. PMID: 22699971.
  • Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, Barrat J, Blanton JD, Briggs DJ, Cleaveland S, et al. Estimating the global burden of endemic canine rabies [published correction appears in PLoS Negl Trop Dis. 2015 May;9(5):e0003786]. PLoS Negl Trop Dis. 2015;9(4):e0003709. doi:10.1371/journal.pntd.0003709. PMID: 25881058.
  • Pichon S, Guinet-Morlot F, Minutello M, Donazzolo Y, Rouzier R, Chassard D, Fitoussi S, Hou V. A serum-free, purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial. Vaccine. 2013;31(18):2295–301. doi:10.1016/j.vaccine.2013.02.058. PMID: 23510665
  • World Health Organization. WHO expert consultation on rabies: third report. WHO; 2008. https://apps.who.int/iris/handle/10665/272364.
  • Guanmu D, Gelin X, Qiyou X, Dingming W, Yuemei H, Dunjin Z, Ping W, Yongzhen Z, Xiaoming Y, Fengcai Z, et al. Epidemiological investigation of rabies virus in domestic dogs, cats, and wild animals and observation on the immune effect of different rabies vaccines in China. Chin J Virol. 2007;23(6):417–23. doi:10.3321/j.1000-8721.2007.06.001.
  • Manrong C, Jie W, Shengli M, Gelin X. Protection of CTN-1V human rabies vaccine prepared by CTN strain against challenge with representative rabies street virus strains in China. Chin J Biol. 2008;21(9):786–87. doi:10.13200/j.cjb.2008.09.55.chengmr.018.
  • Huang T, Li Y, Mo S, Li J, Nan R, Zhou L, Wang M, Nie F, Chen J, Yang T, et al. Safety and immunogenicity of domestic rabies vaccine (Vero cells) for human use prepared with CTN-1V strain in healthy population. Chin J Biologicals. 2018;31(6):624–628, 637. doi:10.13200/j.cnki.cjb.002201.
  • National Medical Products Administration. About printing and distributing six technical guidelines including ”technical guidelines for preclinical study of preventive vaccines”. NMPA; 2005. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20051014010101369_5.html.
  • Ling Z, Tianxi Z, Kewen S, Siwei T, Ji S, Haipeng Y. Evaluation of the efficacy of rapid fluorescent foci inhibition test for the detection of rabies virus neutralizing antibodies. Chin J Health Inspection. 2021;31:2076–79.
  • World Health Organization. Rabies vaccines: WHO position paper, April 2018 - Recommendations. Vaccine. 2018;36(37):5500–03. doi:10.1016/j.vaccine.2018.06.061. PMID: 30107991.
  • Fishbein DB, Yenne KM, Dreesen DW, Teplis CF, Mehta N, Briggs DJ. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study. Vaccine. 1993;11(14):1390–94. doi:10.1016/0264-410x(93)90167-v. PMID: 8310759
  • Yanrong L. Analysis of epidemic characteristics of Chinese rabies from 2007 to 2016 and forecasting of epidemic trends. Jiamusi University; 2018. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CMFD&dbname=CMFD201901&filename=1018876800.nh&uniplatform=NZKPT&v=HPkAOMK-ggFkcTUTzG5227O0CuX7sWxdmYjroS-nP0UCuMNeNrmD45zrKspee1E5.
  • Haupt W. Rabies-risk of exposure and current trends in prevention of human cases. Vaccine. 1999;17(13–14):1742–49. doi:10.1016/s0264-410x(98)00447-2. PMID: 10194833
  • Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, et al. Human rabies prevention-United States, 2008: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2008;57(RR–3):1–28. PMID: 18496505.
  • Xinxiong Z, Yutao Z, Wei C, Wen S, Huafang D, Shi H, Zuolin H, Lingbing Z, Gelin X. Clinical trials of adjuvant-free freeze-dried rabies vaccine for human use. Chin J Biol. 2007;4:276–77. doi:10.13200/j.cjb.2007.04.49.zhengxx.014.
  • Lirong H, Tengrong L, Guiqiu P, Shouchun C, Wei Z, Yuting H, Mingli L, Yanping L. Safety and immunogenicity of freeze-dried rabies vaccine (Vero cells) for human use in healthy population at ages of 10 - 60 years. Chin J Biol. 2017;30(3):283–87. doi:10.13200/j.cnki.cjb.001685.